"In January 2026, CytoDyn (OTCQB: CYDY) announced that an anonymous donor has provided funding to support an Expanded Access Program (EAP) allowing patients with triple-negative breast cancer (TNBC) to receive leronlimab. The company has partnered with WEP Clinical as the CRO and plans to open the program for patient referrals in March 2026, pending FDA approval of a revised protocol. The EAP is designed for patients who have exhausted approved therapies and do not qualify for ongoing clinical trials. The program may also offer insights into PD-L1 induction after leronlimab and potential combination strategies with immune checkpoint inhibitors. Additional details for physicians and patients will be shared on the company's website as the program progresses."
https://www.openpr.com/news/4575914/triple-ne...velopments